Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) in a research report issued to clients and investors on Thursday. The firm set a “hold” rating on the stock.

Several other research firms have also recently commented on SYRS. Oppenheimer cut their target price on Syros Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating on the stock in a research note on Thursday, March 2nd. JMP Securities decreased their price objective on Syros Pharmaceuticals from $16.00 to $15.00 in a report on Thursday, May 11th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Syros Pharmaceuticals in a report on Friday, March 3rd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.75.

Syros Pharmaceuticals Stock Performance

Syros Pharmaceuticals stock opened at $4.08 on Thursday. The stock has a 50-day simple moving average of $2.95 and a 200 day simple moving average of $3.64. The company has a quick ratio of 7.37, a current ratio of 7.37 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $84.05 million, a price-to-earnings ratio of -0.42 and a beta of 1.68. Syros Pharmaceuticals has a 12-month low of $2.42 and a 12-month high of $11.50.

Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) last posted its earnings results on Thursday, March 2nd. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.01). The company had revenue of ($0.75) million for the quarter, compared to analyst estimates of $3.28 million. Syros Pharmaceuticals had a negative return on equity of 118.11% and a negative net margin of 485.12%. On average, research analysts anticipate that Syros Pharmaceuticals will post -4.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several large investors have recently bought and sold shares of SYRS. Assenagon Asset Management S.A. acquired a new stake in shares of Syros Pharmaceuticals in the first quarter valued at about $28,000. Denali Advisors LLC bought a new stake in shares of Syros Pharmaceuticals in the fourth quarter valued at $28,000. Edmond DE Rothschild Holding S.A. purchased a new position in shares of Syros Pharmaceuticals in the third quarter valued at $28,000. Private Advisor Group LLC purchased a new position in shares of Syros Pharmaceuticals in the first quarter valued at $29,000. Finally, Sawtooth Solutions LLC purchased a new position in Syros Pharmaceuticals during the first quarter worth about $29,000. 48.77% of the stock is currently owned by institutional investors.

About Syros Pharmaceuticals

(Get Rating)

Syros Pharmaceuticals, Inc engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.